Opening GPAtlas…

๐ŸŒŠ The Ocean Library ยท GP clinical topic

Serotonin Syndrome

Written and reviewed by practising UK GPs, overseen by our Clinical Advisory Officer.

๐Ÿงญ When to suspect

Serotonin syndrome (serotonin toxicity) is a potentially life-threatening, drug-induced reaction caused by excess serotonergic activity in the central nervous system. It is defined by a clinical triad of altered mental state, autonomic hyperactivity and neuromuscular excitation, and spans a dose-related spectrum from mild, self-limiting effects through to fatal toxicity. It can follow a single drug at a therapeutic dose, but most cases arise from a combination of serotonergic drugs, a recent dose increase, or an overdose.

Onset is characteristically rapid: features usually appear within 24 hours, and about 60% within 6 hours, of starting, increasing or combining a serotonergic drug. Severe, life-threatening toxicity (rigidity and hyperthermia) almost always requires two or more serotonergic agents, one of which is often a monoamine oxidase inhibitor (MAOI). The key skill in primary care is to think of it in any patient on a serotonergic drug with new neuromuscular signs, to examine for clonus, and to diagnose using the Hunter Serotonin Toxicity Criteria rather than waiting for the full triad.

Severity Typical features Action
Mild Tachycardia, shivering, diaphoresis, mydriasis, tremor, mild hyperreflexia; afebrile and haemodynamically stable Often manageable in the community: stop the agent, supportive care, review โ€“ with a low threshold to refer
Moderate Above plus inducible/ocular clonus, agitation, marked hyperreflexia, temperature up to ~40ยฐC, hypertension Emergency hospital assessment
Severe Spontaneous/sustained clonus, truncal rigidity, hyperthermia > 41ยฐC, autonomic instability, delirium or reduced consciousness 999 โ€“ life-threatening; requires intensive care
Drug group Common UK examples (brands)
SSRIs / SNRIs sertraline (Lustral), fluoxetine (Prozac), citalopram, escitalopram, paroxetine (Seroxat); venlafaxine (Efexor), duloxetine (Cymbalta)
MAOIs (incl. "hidden") phenelzine (Nardil), tranylcypromine, isocarboxazid, moclobemide (Manerix); the antibiotic linezolid (Zyvox) and methylene blue
Opioids tramadol (Zydol), pethidine, fentanyl, methadone; dextromethorphan
Other prescribed triptans e.g. sumatriptan (Imigran); lithium; tricyclics e.g. clomipramine (Anafranil); mirtazapine; ondansetron/metoclopramide (weak)
OTC / recreational St John's wort; MDMA ("ecstasy"), amphetamines, cocaine

Source: Hunter Criteria ยท BMJ (Isbister, 2014)


๐Ÿ”’ Sign up free to read the full topic

You're viewing a free preview. Create a free account to unlock the rest.

Sign up free โ†’
Inside the full topic ๐Ÿ”’ History๐Ÿ”’ Red Flags๐Ÿ”’ Examination๐Ÿ”’ Patient Explanation๐Ÿ”’ Investigations๐Ÿ”’ Management๐Ÿ”’ Non-pharmacological Treatment๐Ÿ”’ Pharmacological Treatment๐Ÿ”’ Special Notes๐Ÿ”’ Referral Pathways๐Ÿ”’ Take Home Messages

Sample topics are open to everyone in the Free Sample Bundle.

Part of The Ocean Library, 450+ structured clinical topics mapped to the primary care curriculum. Companion audio in Echo ยท one-page summary in The Scope.

We use cookies to enhance your browsing experience, provide personalised content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Privacy policy